Here are six new drug shortages and discontinuations, according to drug supply databases from the FDA and American Society of Health-System Pharmacists.
- Pemetrexed disodium injection: Multiple presentations of pemetrexed disodium injection, including 100 milligram and 500 milligram vials, have been discontinued. The drug is used in combination with other therapies for non-small cell lung cancer and mesothelioma.
- Adalimumab biosimilars: Adalimumab-afzb and Abrilada, both biosimilars to Humira, have been discontinued. These injections are used to treat rheumatoid arthritis, Crohn’s disease and other autoimmune conditions.
- Hydrocortisone sodium succinate injection: Hydrocortisone sodium succinate 100 milligram vials are in limited supply due to increased demand. The corticosteroid is used for allergic reactions, adrenal insufficiency and inflammation.
- Paricalcitol capsules: The 1, 2 and 4 microgram oral capsule strengths of paricalcitol from Bionpharma and Time-Cap Labs are in shortage. Bionpharma’s products are on allocation and Time-Cap’s are on backo=rder with no estimated resupply date. The FDA also listed the 1 and 2 microgram formulations as discontinued.
- Cobicistat tablets: Cobicistat 150 milligram tablets, marketed as Tybost, are being discontinued for business reasons. Supply is expected to continue through February 2026. Cobicistat is used as a pharmacokinetic enhancer in HIV treatment.
- Omeprazole delayed-release capsules: Omeprazole capsules have been discontinued. The proton pump inhibitor is commonly used to treat gastroesophageal reflux disease and other acid-related gastrointestinal conditions.
